Publicacións nas que colabora con Federico Argüelles Arias (29)

2024

  1. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 5, pp. 604-612

  2. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

  3. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 5, pp. 522-552

2023

  1. Effectiveness and safety of ustekinumab in bio-naïve Crohn’s disease patients: a multicentre observational retrospective study

    Therapeutic Advances in Gastroenterology, Vol. 16

  2. Optimizing treatment of mild to moderate ulcerative colitis: CU-forum Delphi consensus

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 10, pp. 784-794

2022

  1. Co-09. Efectividad y seguridad de ustekinumab en enfermedad de crohn en pacientes bionaive: Un estudio multicéntrico

    Revista andaluza de patología digestiva, Vol. 45, Núm. 5, pp. 206-208

  2. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  3. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  4. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  5. Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 3, pp. 165-176

  6. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

  7. Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 16, Núm. 6, pp. 946-953

  8. Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study

    Digestive and Liver Disease, Vol. 54, Núm. 1, pp. 76-83

  9. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study

    Alimentary pharmacology & therapeutics, Vol. 53, Núm. 12, pp. 1277-1288

2020

  1. Consensus document on the management preferences of patients with ulcerative colitis: points to consider and recommendations

    European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 12, pp. 1514-1522

  2. Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: The VERNE study

    BMJ Open Gastroenterology, Vol. 7, Núm. 1

2019

  1. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU

    Alimentary Pharmacology and Therapeutics, Vol. 49, Núm. 4, pp. 419-428

  2. Increased risk of thiopurine-related adverse events in elderly patients with IBD

    Alimentary Pharmacology and Therapeutics, Vol. 50, Núm. 7, pp. 780-788

  3. Prevalence and Factors Associated with Fatigue in Patients with Inflammatory Bowel Disease: A Multicentre Study

    Journal of Crohn's and Colitis, Vol. 13, Núm. 8, pp. 996-1002